Not all sufferers with CLL call for therapy. In spite of all the latest improvements, the iwCLL nevertheless endorses watchful observation for patients with asymptomatic illness.86 This recommendation is based on at least two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 Both trials https://trentoniifij.bloginder.com/33101758/a-secret-weapon-for-link-alternatif-mbl77